Stocks › ALKS
Alkermes plc.
ALKS·Nasdaq·
Ireland·USD
Ireland·USD$41.65
-1.11 (-2.60%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
ALKS
Alkermes plc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ALKSS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ALKS by members of U.S. Congress · 1 on record · 1 in the last 12 months
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Gilbert Ray Cisneros, Jr.House · D · CA |
ALKSAlkermes plc. · Stock |
Purchase $15,001 - $50,000 |
Sep 4, 2026 | Jul 30, 2026 | Filing ↗ |
Whale Activity
Position changes in ALKS reported for 2026-06-30 by 16 tracked institutional filers
- Increased5
- New1
- Held0
- Decreased2
- Closed1
- No prior filing7
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 29.2M | $1.53B | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 9.5M | $497.3M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.5M | $393.7M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 6.5M | $338.5M | increased |
| BVF INC/IL | 2.2M | $112.9M | — |
| CITADEL ADVISORS LLC | 1.6M | $86.2M | decreased |
| D. E. Shaw & Co., Inc. | 1.3M | $68.7M | increased |
| Affinity Asset Advisors, LLC | 1.1M | $58.9M | — |
| TWO SIGMA INVESTMENTS, LP | 1.0M | $54.4M | increased |
| MILLENNIUM MANAGEMENT LLC | 319.6K | $16.7M | new |
| Senator Investment Group LP | 275.0K | $14.4M | — |
| Palo Alto Investors LP | 242.6K | $12.7M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ALKS insiders, by quarter · Form 4
Recent Insider Transactions
3,242 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sale | −2,034 | $41.03 | $83K | Oct 2, 2026 | Form 4 ↗ |
| Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sale | −2,034 | $48.01 | $98K | Sep 3, 2026 | Form 4 ↗ |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | −9,000 | $46.99 | $423K | Sep 1, 2026 | Form 4 ↗ |
| Nichols Christian ToddSVP, Chief Commercial Officer | Sale | −6,912 | $49.19 | $340K | Aug 17, 2026 | Form 4 ↗ |
| Nichols Christian ToddSVP, Chief Commercial Officer | Sale | −664 | $49.65 | $33K | Aug 17, 2026 | Form 4 ↗ |
| snyderman nancy lynn MDDirector · Director | Sale | −44.5K | $50.35 | $2.2M | Aug 3, 2026 | Form 4 ↗ |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | −9,000 | $48.58 | $437K | Aug 3, 2026 | Form 4 ↗ |
| Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sale | −2,034 | $48.58 | $99K | Aug 3, 2026 | Form 4 ↗ |
| Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sale | −2,034 | $54.03 | $110K | Jul 6, 2026 | Form 4 ↗ |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | −8,300 | $51.46 | $427K | Jul 1, 2026 | Form 4 ↗ |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | −700 | $52.13 | $36K | Jul 1, 2026 | Form 4 ↗ |
| Wright Christopher IDirector | Sale | −2,000 | $45.10 | $90K | Jun 12, 2026 | Form 4 ↗ |
| Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sale | −2,034 | $43.05 | $88K | Jun 4, 2026 | Form 4 ↗ |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | −9,000 | $41.67 | $375K | Jun 1, 2026 | Form 4 ↗ |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Option exercise | +5,000 | $19.34 | $97K | Jun 1, 2026 | Form 4 ↗ |
| Parisi Samuel JosephVP, Finance (Interim PAO) | Sale | −16.2K | $42.36 | $687K | May 29, 2026 | Form 4 ↗ |
| Parisi Samuel JosephVP, Finance (Interim PAO) | Option exercise | +12.8K | $19.34 | $248K | May 29, 2026 | Form 4 ↗ |
| Parisi Samuel JosephVP, Finance (Interim PAO) | Option exercise | +3,392 | $20.03 | $68K | May 29, 2026 | Form 4 ↗ |
| Wright Christopher IDirector | Tax withholding | −1,475 | $36.95 | $55K | May 21, 2026 | Form 4 ↗ |
| Wright Christopher IDirector | Option exercise | +6,142 | — | — | May 21, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ALKS · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 5.3M | $277.6M | 0.01% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 3.8M | $200.3M | 0.11% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF American Century ETF Trust | 3.3M | $137.8M | 0.51% | May 31, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 2.2M | $115.4M | 0.25% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.9M | $100.2M | 0.10% | Jun 30, 2026 |
| VANGUARD CAPITAL OPPORTUNITY FUND VANGUARD HORIZON FUNDS | 1.7M | $89.9M | 0.27% | Jun 30, 2026 |
| VANGUARD TAX-MANAGED SMALL-CAP FUND VANGUARD TAX-MANAGED FUNDS | 1.1M | $56.4M | 0.49% | Jun 30, 2026 |
| Small Cap Growth Fund American Century Mutual Funds, Inc. | 993.4K | $48.7M | 0.87% | Jul 31, 2026 |
| College Retirement Equities Fund - Total Global Stock Account College Retirement Equities Fund | 703.1K | $36.8M | 0.03% | Jun 30, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 833.4K | $35.2M | 0.20% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list ALKS's shares (CUSIP G01767105), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- T. Rowe Price Associates, Inc.SCHEDULE 13G/A · passive (13G) · 4.7M shares2.8%
May 15, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming alkermes as client
Government Contracts
Federal awards to Alkermes plc. · USAspending
No federal contract awards found for Alkermes plc..
U.S. Patents
Recent USPTO applications naming Alkermes plc.
No USPTO patent applications found for Alkermes plc..
Annual Financials
From ALKS's 10-K filings · XBRL
No annual XBRL figures on record for ALKS. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 2-for-1Stock splitMay 15, 2000
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsSep 21, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureSep 16, 2026
EDGAR ↗ - 8-K · Items 1.01, 9.01Material agreementAug 12, 2026
EDGAR ↗ - 8-K/A · Items 5.02Officer / director changeAug 3, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 28, 2026
EDGAR ↗ - 8-K · Items 1.02Termination of agreementJul 8, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsJun 15, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteMay 20, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsMay 12, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
EDGAR ↗
About Alkermes plc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersDUBLIN 4, Ireland
SEC CIK0001520262 ↗
Former namesANTLER SCIENCE TWO PLC, Antler Science Two Ltd